NCT01542021 is a NA clinical trial of degarelix injection in Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Who is sponsoring NCT01542021?

NCT01542021 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT01542021?

Interventions in NCT01542021: degarelix injection, degarelix injection, androgen deprivation therapy.

What condition does NCT01542021 study?

NCT01542021 studies Prostate Cancer, Prostatic Adenocarcinoma.

Is NCT01542021 still recruiting?

NCT01542021 is currently completed. Last updated 3 October 2024.

Last reviewed 2024-10-03 · How we verify

NCT01542021

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer

Completed NA Last updated 3 October 2024

What this trial tests

NA trial testing degarelix injection in Prostate Cancer in 41 participants. Completed in 30 September 2024.

Timeline

24 February 2012

Primary endpoint
30 September 2024

30 September 2024

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	24 February 2012
Primary completion	30 September 2024
Estimated completion	30 September 2024
Sites	1 location across United States

Drugs / interventions tested

degarelix injection — full drug profile →
degarelix injection — full drug profile →
androgen deprivation therapy — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Prostatic Adenocarcinoma — all drugs for Prostatic Adenocarcinoma →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, male only, with Prostate Cancer or Prostatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Degarelix is an approved drug that is used to treat prostate cancer by lowering testosterone levels in the body. Degarelix is commonly given with radiation for prostate cancer, but less frequently with surgery since there has been no proven benefit with this approach. The investigators do not expect the patient to benefit directly from treatment with degarelix since their prostate will be removed shortly after the drug is given. Instead, the investigators hope to learn about how degarelix and other treatment that lowers your testosterone effects prostate cancer cells and use this information to develop better treatments in the future.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers.
Fang D, Zhou L. · · 2019 · cited 21× · PMID 30729683 · DOI 10.1111/ajco.13108
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
Dallos MC, Obradovic AZ, McCann P, Chowdhury N, et al · · 2024 · cited 15× · PMID 39269310 · DOI 10.1158/1078-0432.ccr-24-0060
Degarelix for treating advanced hormone-sensitive prostate cancer.
Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, et al · · 2021 · cited 14× · PMID 34350976 · DOI 10.1002/14651858.cd012548.pub2
Will phenotype help guide immunotherapy in prostate cancer?
Tisseverasinghe S, Niazi T. · · 2025 · PMID 40386267 · DOI 10.21037/tcr-2024-2477

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01542021 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 3 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01542021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing